Recent uptick might appease Sangamo Therapeutics, Inc. (NASDAQ:SGMO) institutional owners after losing 82% over the past year
Key Insights
-
Significantly high institutional ownership implies Sangamo Therapeutics' stock price is sensitive to their trading actions
-
The top 9 shareholders own 51% of the company
-
Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company
A look at the shareholders of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) can tell us which group is most powerful. We can see that institutions own the lion's share in the company with 60% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
After a year of 82% losses, last week’s 18% gain would be welcomed by institutional investors as a likely sign that returns might start trending higher.
Let's delve deeper into each type of owner of Sangamo Therapeutics, beginning with the chart below.
Check out our latest analysis for Sangamo Therapeutics
What Does The Institutional Ownership Tell Us About Sangamo Therapeutics?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
Sangamo Therapeutics already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Sangamo Therapeutics, (below). Of course, keep in mind that there are other factors to consider, too.
Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. Sangamo Therapeutics is not owned by hedge funds. Biogen Inc. is currently the largest shareholder, with 13% of shares outstanding. With 9.6% and 9.0% of the shares outstanding respectively, Wasatch Advisors LP and BlackRock, Inc. are the second and third largest shareholders.
We did some more digging and found that 9 of the top shareholders account for roughly 51% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.